Glutaminase 1 (GLS1) is well-recognized for driving glutaminolysis to sustain tumor growth. However, recent research highlights a significant non-metabolic role for GLS1 HNSCC Angiogenesis. New evidence suggests that GLS1 orchestrates communication between tumor cells and the endothelium via exosomes. This process effectively facilitates the formation of new blood vessels, which is critical for the progression of head and neck squamous cell carcinoma (HNSCC).

The study utilized HNSCC xenograft models to observe the effects of GLS1 silencing. Researchers found that genetic depletion of GLS1 or pharmacological inhibition using CB-839 significantly reduced intratumoral angiogenesis. Interestingly, exosomes from GLS1-deficient cells failed to promote endothelial cell migration and tube formation. Proteomic analysis further identified Tenascin C (TNC) as a key pro-angiogenic protein missing from these exosomes.

Investigating the Mechanism of GLS1 HNSCC Angiogenesis

The molecular pathway specifically involves the deubiquitinase USP1. Normally, GLS1 maintains USP1-mediated deubiquitination of Caveolin-1 (CAV1). When GLS1 is lost, CAV1 undergoes rapid degradation. This loss subsequently impairs the recruitment of TNC into exosomes. Therefore, the resulting CAV1-TNC-deficient exosomes cannot activate integrin-dependent FAK-SRC signaling in endothelial cells. This interruption successfully inhibits their angiogenic activity.

These findings are clinically significant for oncologists and surgeons in India. Because HNSCC remains highly prevalent in the region, understanding these dual roles of GLS1 is vital. Targeting this enzyme could simultaneously disrupt tumor metabolism and the supporting vascular network. Moreover, this dual-action approach may provide more robust outcomes compared to conventional metabolic inhibitors used alone.

Frequently Asked Questions

What is the primary role of GLS1 in HNSCC?

GLS1 primarily drives glutaminolysis to support tumor growth, but it also promotes angiogenesis by modulating exosome-mediated signaling pathways.

How does GLS1 loss affect endothelial cells?

Losing GLS1 leads to the degradation of Caveolin-1, preventing the inclusion of Tenascin C in exosomes. Without these proteins, endothelial cells cannot activate FAK-SRC signaling, which stops them from forming new blood vessels.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional clinical judgment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Yang J et al. GLS1 Orchestrates Exosome-Mediated Tumor-Endothelial Communication to Facilitate Angiogenesis. Adv Sci (Weinh). 2026 May 03. doi: 10.1002/advs.75510. PMID: 42070227.

Li B et al. Therapeutic Targeting of the GLS1-c-Myc Positive Feedback Loop Suppresses Glutaminolysis and Inhibits Progression of Head and Neck Cancer. Cancer Res. 2024 Oct 1;84(19):3197-3211.

Pang X et al. Exosomes: Potential Biomarkers and Functions in Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol. 2022 Jun 13;10:904500.